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Background: To observe the relationship between serum retinol binding protein 4(RBP4) and β cell function in
Chinese subjects with non-alcoholic fatty liver disease (NAFLD) and without known diabetes.
Methods: 106 patients diagnosed as fatty liver by ultrasonography (M/F: 61/45; aged 47.44 ± 14.16 years) were
enrolled in our current cross-sectional study. Subjects with known diabetes, chronic virus hepatitis and excessive
alcohol consumption were excluded. Serum RBP4 was detected by ELISA and validated by quantitative Western
blotting. β cell function were assessed by HOMA in all subjects and by hyperglycemic clamp in 17 normal glucose
tolerance subjects (M = 6, F = 11).
Results: The levels of serum RBP4 in men were higher than that in women (55.96 ± 11.14 vs 45.87 ± 10.31 μg/ml,
p < 0.001). Pearson’s correlation analysis demonstrated that in women, serum RBP4 levels were significantly
associated with fasting blood glucose (FBG), HOMA-β, and increment of first phase insulin secretion (1PH), but
not associated with age, BMI, waist circumference, WHR, systolic (SBP) and diastolic blood pressure (DBP), TC, TG,
HDL-c, LDL-c, 2 h blood glucose, HOMA-IR, ALT, AST, γ-GT, hepatic fat content (HFC), and insulin sensitivity index
(ISI). However, in men, serum RBP4 levels were significantly associated with HDL-c, ALT, AST, but not associated
with any other parameters as mentioned above. A stepwise multiple linear regression analysis demonstrated
that in women, HOMA-IR and RBP4 were significantly associated with HOMA-β, while in men, HOMA-IR and BMI
were significantly variables associated with HOMA-β.
Conclusions: Serum RBP4, secreted mainly by liver and adipose tissue, may involve in the pathogenesis of β cell
dysfunction in Chinese women patients with NAFLD.
Keywords: Serum retinol binding protein 4 (RBP4), Beta cell function, Non-alcoholic fatty liver disease (NAFLD)Background
Retinol binding protein 4 (RBP4) is a member of the
lipocalin family of proteins that transport retinol from
the liver to the peripheral tissues and plasma RBP4 levels
positively correlate with retinol levels.
A potential link between RBP4 and type 2 diabetes mel-
litus was suggested by Yang et al. [1]. The study reported* Correspondence: zhongshan_endo@126.com
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reproduction in any medium, provided the orthat RBP4 was elevated in insulin-resistant mice with adi-
pose tissue-specific GLUT4 knockout and humans with
obesity and type 2 diabetes mellitus. They found that
RBP4 expression was increased in insulin resistant adipose
tissue specific GLUT4 null mice and reduced in insulin
sensitive adipose specific GLUT4 transgenics mice. Trans-
genic overexpression of human RBP4 or injection of re-
combinant RBP4 in normal mice causes insulin resistance
and glucose intolerance. Conversely, genetic deletion of
Rbp4 enhances insulin sensitivity.. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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RBP4 levels were elevated in subjects with IGT or type
2 diabetes mellitus and that RBP4 was related to various
clinical parameters known to be associated with insulin
resistance. And a cross-sectional study conducted in
Chinese found that increased RBP4 levels increased the
risk for hyperglycemia, including impaired glucose regula-
tion and newly diagnosed type 2 diabetes mellitus, even
after adjustment for a number of confounders [4]. These
studies suggested that RBP4 was an adverse impact factor
of diabetes mellitus.
Some researchers explored the relationship of RBP4 and
insulin resistance. It was reported that serum RBP4 levels
associated negatively with insulin sensitivity (determined
by a hyperinsulinemic euglycemic clamp) in non-diabetic
[5] or impaired glucose metabolism participants [6] and in
women with polycystic ovary syndrome [7] or in women
with normal glucose tolerance with different obesity [8].
However, the associations between RBP4 levels and insulin
resistance were not consistent. Several studies failed to
find a significant correlation between RBP4 levels and
insulin resistance [9,10]. The suggested explanations for
these discrepancies include the differences in renal clear-
ance of RBP4 caused by the different renal functions in
the study subjects, the imbalance between RBP4 and ret-
inol, the influence of the collection method, and the anti-
bodies used in measuring RBP4 [11].
Since the relationship between RBP4 and insulin resist-
ance was controversial, and impaired β-cell was another
important pathogenesis of diabetes mellitus, the relation-
ship between β cell function and RBP4 need to be further
studied. However, few studies showed their relation at
present.
Our earlier work found that, the first phase or early
phase of insulin secretion were impaired in non-alcoholic
fatty liver disease (NAFLD) patients when their hepatic fat
content detected by 1H MRS or CT were more than 10%,
which indicated that liver cell with excessive fat deposition
may release some cytokines to affect the beta cell function
[12,13]. Recent studies found that levels of serum RBP4
were increased in NAFLD patients [14], so we speculated
that the serum RBP4 may be one of cytokines involved in
the cross-talk of adipose tissue and beta cell function in
patients with fatty liver.
Thus, the purpose of the present study was to investigate
correlations between serum RBP4 levels and β-cell func-
tion in Chinese NAFLD subjects without known T2DM.
Results
The clinical characteristics of the subjects are shown
in Tables 1 and 2. The women participants were older
than men participants. Compared to women, men had
higher waist circumference and waist-to-hip ratio (WHR),
triglycerides (TG), alanine aminotransferase (ALT),γ-glutamyltranspeptidase (γ-GT), serum RBP4, hepatic fat
content, and lower high-density lipoprotein cholesterol
(HDL-c). There are no differences between men and
women in body mass index (BMI), systolic and diastolic
blood pressure, total cholesterol (TC), low-density lipo-
protein cholesterol (LDL-c), fasting blood glucose (FBG)
and 2 hour blood glucose (2hBG), fasting insulin (FINS)
and 2 hour insulin (2hINS), HOMA-IR, HOMA-β, the in-
sulin sensitivity index (ISI), First-phase insulin secretion
(1PH), Increment of 1PH, Second-phase insulin secretion
(2PH), Increment of 2PH, aspartate aminotransferase
(AST), alkaline phosphatase (ALP).
In all the subjects, serum RBP4 levels were signifi-
cantly associated with sex, waist circumference, WHR,
SBP, DBP, TG, HDL-c, γ-GT, but not associated with
age, BMI, TC, LDL-c, FBG, 2hBG, FINS, 2hINS,
HOMA-IR, HOMA-β, ALT, AST, ALP, HFC. ISI, 1PH,
Increment of 1PH, 2PH, Increment of 2PH. In women,
serum RBP4 levels were significantly associated with
FBG, HOMA-β, Increment of 1PH; but not associated
with age, BMI, and the other variables mentioned above.
While in men, serum RBP4 levels were significantly asso-
ciated with HDL-c, ALT, AST, but not associated with
age, BMI, and the other variables mentioned above, either
(Tables 3 and 4).
A stepwise multiple linear regression analysis was
performed using HOMA-β as a dependent variable. RBP4
was selected as an independent variable together with age,
BMI, HFC, ALT, AST, γ-GT, waist circumference, WHR,
SBP, DBP, TC, TG, HDL-c, LDL-c, HOMA-IR in all
subjects. We also performed stepwise multiple linear
regression analysis within each gender. In all subjects,
HOMA-IR (Standardized Coefficients Beta = 0.626,
p <0.001) together with age (Standardized Coefficients
Beta = -0.245, p =0.013) were determined as significant vari-
ables associated with HOMA-β. In women, HOMA-IR
(Standardized Coefficients Beta =0.521, p =0.001) and RBP4
(Standardized Coefficients Beta = -0.415, p =0.005) were sig-
nificant variables associated with HOMA-β. While in men,
HOMA-IR (Standardized Coefficients Beta =0.591,
p <0.001) and BMI (Standardized Coefficients Beta =0.328,
p =0.013) were significant variables associated with
HOMA-β (Table 5).
Discussion
In the current study we found that serum RBP4 levels were
inversely associated with β cell function in a cohort of
Chinese women NAFLD patients without known diabetes
mellitus. To the best of our knowledge, this study is the
first showing a quantitative correlation between serum
RBP4 levels and beta cell function assessed not only by
HOMA-β but also by hyperglycemic clamp in Chinese
NAFLD patients. Our study added to the growing evi-
dences that serum RBP4,which secreted mainly by liver
Table 1 Basic characteristics of all the subjects
Total (n = 106) Men (n = 61) Women (n = 45) P value
Age (y) 47.39 ± 13.88 44.70 ± 15.21 50.98 ± 11.04 0.016
BMI (kg/m2) 26.69 ± 3.48 26.90 ± 3.45 26.39 ± 3.54 0.459
Waist (cm) 91.88 ± 10.04 94.26 ± 9.59 88.64 ± 9.82 0.004
WHR 0.92 ± 0.07 0.95 ± 0.06 0.89 ± 0.07 <0.001
Systolic blood pressure (mmHg) 129.05 ± 19.57 130.67 ± 16.57 126.84 ± 23.04 0.322
Diastolic blood pressure (mmHg) 81.45 ± 11.25 82.93 ± 10.50 79.44 ± 12.02 0.115
Total cholesterol (mmol/L) 4.97 ± 0.83 4.93 ± 0.77 5.03 ± 0.92 0.532
Triglycerides (mmol/L)lg 2.15 ± 1.22 2.54 ± 1.37 1.63 ± 0.74 <0.001
HDL-c (mmol/L)lg 1.16 ± 0.26 1.06 ± 0.18 1.30 ± 0.27 <0.001
LDL-c (mmol/L) 2.89 ± 0.69 2.81 ± 0.62 2.98 ± 0.76 0.217
Fasting blood glucose (mmol/L)lg 5.33 ± 0.76 5.31 ± 0.80 5.35 ± 0.72 0.832
2 h blood glucose (mmol/L)lg 7.30 ± 2.52 7.08 ± 2.51 7.62 ± 2.53 0.289
Fasting insulin (mU/L)lg 10.85 ± 6.95 10.29 ± 7.01 11.61 ± 6.89 0.354
2 h insulin (mU/L)lg 80.51 ± 61.67 77.54 ± 66.68 84.74 ± 54.30 0.574
HOMA-IRlg 2.62 ± 1.76 2.46 ± 1.81 2.84 ± 1.70 0.289
HOMA-βlg 138.36 ± 110.55 136.84 ± 122.41 140.42 ± 93.48 0.874
ALT (U/L)lg 47.23 ± 43.10 56.64 ± 47.86 34.82 ± 32.42 0.011
AST (U/L)lg 33.12 ± 20.13 34.51 ± 19.96 31.24 ± 20.45 0.427
ALP (U/L) 73.06 ± 20.76 74.87 ± 21.86 70.68 ± 19.22 0.333
γ-GT (U/L)lg 49.79 ± 48.67 60.62 ± 58.24 35.54 ± 26.57 0.006
Serum RBP4 (μg/ml) 51.65 ± 11.85 55.96 ± 11.14 45.87 ± 10.31 <0.001
Hepatic fat content (%)lg 7.90 ± 6.89 9.10 ± 6.85 6.26 ± 6.66 0.035
Data are means ± S.D. BMI: body-mass index, WHR: waist-to-hip ratio, HDL-c: high-density lipoprotein cholesterol, LDL-c: low-density lipoprotein cholesterol,
HOMA-IR: homeostatic model assessment of insulin resistance, HOMA-β:homeostatic model assessment of β cell function, ALT: alanine aminotransferase,
AST: aspartate aminotransferase, γ-GT: γ-glutamyltransferase, RBP4: retinol binding protein 4.
lg: logarithmic transformation with 10 as its base of skewed variables.
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for beta cell function and diabetes mellitus mellitus. In
addition, the serum RBP4 might be one of cytokines in-
volved in the cross-talk between adipose tissue and beta
cell function in patients with fatty liver.
So far, a total of 3 articles reported the relationship be-
tween circulating RBP4 and β cell insulin secretion.
Similarly, two studies have found that RBP4 negatively
related to beta cell function. But the study population
and methods to assess insulin secretion were different.
Broch et al. reported that [15] circulating RBP4 was
negatively associated with acute insulin response (AIRg)
(r = -0.48, P = 0.007), calculated as the insulin area duringTable 2 Basic characteristics of NGT subjects underwent hype
Total (n = 17)
Insulin sensitivity index (ISI) 15.48 ± 14.41
First-phase insulin secretion (1PH) 288.32 ± 169.41
Increment of 1PH 77.45 ± 41.96
Second-phase insulin secretion (2PH) 120.33 ± 67.90
Increment of 2PH 207.75 ± 145.92the first 10 min of the frequently sampled intravenous glu-
cose tolerance test, in 107 Spanish men without diabetes
mellitus, especially in obese subjects. In multiple regres-
sion analyses to predict insulin secretion, RBP4 emerged
as an independent factor that contributed independently
to AIRg variance (23%) in obese but not in nonobese sub-
jects. There were no related information about women in
this study. Another study investigated 867 non-obese
Chinese patients with NGT [16] and showed that serum
RBP4 correlated with glucose-stimulated insulin secretion,
assessed by ΔI30/ΔG30 (increment in plasma insulin con-
centration plasma glucose concentration 30 min after the
oral administration of 75 g glucose) and the total arearglycemic clamp
Men (n = 6) Women (n = 11) P value
13.55 ± 15.50 16.53 ± 14.45 0.698
304.60 ± 161.52 279.45 ± 180.64 0.780
85.57 ± 33.54 73.01 ± 46.83 0.572
110.21 ± 50.41 125.84 ± 77.53 0.665
216.91 ± 104.04 202.76 ± 169.05 0.856
Table 3 Pearson’s correlation analysis of serum RBP4 in all the subjects
Total (n = 106) Men (n = 61) Women (n = 45)
r P r P r P
Gender −0.423 0.000
Age (y) 0.061 0.574 0.114 0.432 0.252 0.126
BMI (kg/m2) 0.048 0.653 0.034 0.814 −0.018 0.915
Waist (cm) 0.218 0.040 0.069 0.632 0.121 0.468
WHR 0.343 0.001 0.139 0.332 0.264 0.109
Systolic blood pressure (mmHg) 0.247 0.020 0.138 0.332 0.299 0.068
Diastolic blood pressure (mmHg) 0.241 0.023 0.196 0.167 0.124 0.458
Total cholesterol (mmol/L) 0.095 0.382 0.175 0.228 0.076 0.652
Triglycerides (mmol/L)lg 0.330 0.002 0.124 0.398 0.188 0.257
HDL-c (mmol/L)lg −0.392 <0.001 −0.281 0.059 −0.183 0.279
LDL-c (mmol/L) 0.049 0.658 0.108 0.476 0.113 0.504
Fasting blood glucose(mmol/L)lg 0.063 0.556 −0.123 0.390 0.322 0.048
2 h blood glucose (mmol/L)lg −0.045 0.676 −0.142 0.322 0.277 0.097
Fasting insulin (mU/L)lg −0.051 0.641 0.164 0.266 −0.271 0.104
2 h insulin (mU/L)lg −0.039 0.729 −0.089 0.546 −0.010 0.954
HOMA-IRlg −0.095 0.387 0.119 0.422 −0.211 0.210
HOMA-βlg −0.101 0.360 0.106 0.472 −0.326 0.049
ALT (U/L)lg 0.105 0.335 −0.287 0.048 0.168 0.312
AST (U/L)lg −0.077 0.487 −0.304 0.038 0.055 0.752
ALP (U/L) 0.116 0.310 −0.007 0.962 0.171 0.326
γ-GT (U/L)lg 0.239 0.034 0.142 0.357 0.042 0.810
Hepatic fat content (%)lg 0.199 0.071 0.048 0.737 0.160 0.339
Data are means ± S.D. BMI: body-mass index, WHR: waist-to-hip ratio, HDL-c: high-density lipoprotein cholesterol, LDL-c: low-density lipoprotein cholesterol,
HOMA-IR: homeostatic model assessment of insulin resistance, HOMA-β: homeostatic model assessment of β cell function, ALT: alanine aminotransferase,
AST: aspartate aminotransferase, γ-GT: γ-glutamyltransferase, RBP4: retinol binding protein 4.
lg: logarithmic transformation with 10 as its base of skewed variables.
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NGT non-visceral obesity subjects, but not in NGT
visceral obesity subjects and T2DM patients.
This study and the two studies mentioned above all
demonstrated that circulating RBP4 may negatively
affect β cell function in different subjects. On the con-
trary, Stefan et al. found that [17] circulating RBP4 did
not correlate with insulin secretion (measured by the
IVGTT and OGTT) before or after adjustment for age,
sex, and insulin sensitivity in a total of 75 Caucasians
without type 2 diabetes mellitus. One of the reasons forTable 4 Pearson’s correlation analysis of serum RBP4 in NGT
Total (n = 17)
r P
Insulin sensitivity index (ISI) −0.279 0.295
First-phase insulin secretion (1PH) −0.307 0.247
Increment of 1PH −0.420 0.105
Second-phase insulin secretion (2PH) 0.008 0.976
Increment of 2PH 0.234 0.382this difference may due to different study subjects, an-
other reason may be the excessive adjustment for gen-
der. If the author analyzed the relationship of RBP4 and
β cell function in men or women respectively, there
might be different results.
It is well known that retinol is pathophysiologically
linked to β cell function [18,19]. On the other hand,
retinol-binding protein circulates in serum, forming a
complex with transthyretin (TTR), a transport protein for
thyroxine. An investigation disclosed that TTR constitutes
a functional component in pancreatic β cell stimulus-subjects underwent hyperglycemic clamp
Men (n = 6) Women (n = 11)
r P r P
−0.753 0.142 −0.035 0.919
0.032 0.960 −0.588 0.057
−0.613 0.272 −0.689 0.019
0.537 0.350 −0.046 0.894
0.530 0.359 0.143 0.674
Table 5 Multiple linear regression analysis
Coefficients
Model Unstandardized coefficients Standardized coefficients t Sig.
B Std. error Beta
All HOMA-IR 0.090 0.014 0.626 6.538 0.000
Age −0.005 0.002 −0.245 −2.563 0.013
Men HOMA-IR 0.076 0.016 0.591 4.728 0.000
BMI 0.026 0.010 0.328 2.625 0.013
Women HOMA-IR 0.085 0.022 0.521 3.817 0.001
RBP4 −0.012 0.004 −0.415 −3.039 0.005
A stepwise multiple linear regression analysis was performed using HOMA-β as a dependent variable, RBP4 was selected as an independent variable together with
age, BMI, waist circumference, Hepatic fat content, alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, waist-to-hip ratio, Systolic and
Diastolic blood pressure, Total cholesterol, Triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, HOMA-IR.
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to the receptor [21]. Thus, it is possible that increased
serum RBP4 prevents TTR from exerting its β-cell
stimulus-secretion effects. In fact, circulating RBP4 is
highly bound to TTR in a one-for-one stoichiometric ra-
tio, and there is little or no “free RBP4” in circulation [22].
In a recent study [23] using gel filtration chromatography
to analyze the RBP4-TTR complex, it was found that
increased serumRBP4 remains bound to TTR in insu-
lin resistant states. Because the affinity of RBP4-TTR
binding is very strong [22], the relative stoichiometry
and affinity of the two proteins in serum could con-
ceivably influence kinetics of RBP4-antibody binding.
The concentration of serum RBP4 varies by gender,
generally lower in women than in men, both among
adults and children [2,24,25]. Several previous studies
hypothesized that sex hormones may play a role in the
gender discrepancy. In support of this hypothesis,
RBP4 levels were shown to be different between pre-
menopausal and postmenopausal women [26] and vary
according to pubertal status [27]. Although serum
RBP4 concentration was higher in men than in women,
whereas serum RBP4 didn’t show adverse effect on β
cell function of men, which suggested there may be
some protective factors, such as testosterone, against
RBP4 adverse effect on β cell. McInnes et al. found that
androgen receptor (AR) signaling in adipocytes not
only protects against high-fat diet induced visceral
obesity but also regulates insulin action and glucose
homeostasis, independent of adiposity. Androgen defi-
ciency in adipocytes in mice resembles human type 2
diabetes mellitus, with early insulin resistance and
evolving insulin deficiency [28]. Palomar et al. found
[29] that testosterone, other than progesterone nor es-
tradiol, protects the β cells of men pancreas against
STZ-induced apoptosis, which is sex specific and could
be mediated through the induction of catalase and Cu/
Zn-SOD. It demonstrated that androgens may protect
β cell function in men.The relationship about RBP4 negatively related to beta
cell function, restricted to some, but not all of the study
population, which suggested that their relationship was
complicated and influenced by many other confounding
factors and deserved further research.
Limitations
Firstly, the cross-sectional design of the study represents a
limitation, implicating that cause-and-effect relationships
cannot be discerned. Secondly, we used CT as a tool to de-
termine the hepatic fat content, and its diagnostic accur-
acy is inferior to pathological diagnosis by liver biopsy.
Thirdly, we did not measure blood glucose and insulin at
30 min, so we could not analyze the relationship of serum
RBP4 and early phase of insulin secretion. Finally, due to
the limitation of conditions, there were only 17 NGT pa-
tients undertook clamps in this study. Hence, correlation
analysis of serum RBP4 and the increment of 1PH was
underpowered because the sample size was too small. So,
the data came from hyperglycemic clamp could just be
considered as a clue, the real relationship of RBP4 and
1PH or increment of 1PH needs further verification by
large-scale studies.
In summary, our results suggest that serum RBP4 may
negatively affect β-cell function in Chinese women
NAFLD patients without known diabetes mellitus.
Subjects, materials and methods
Subjects
This is a cross-sectional study. A total of 106 subjects of
Chinese origin (HanChinese) (61 men and 45 women) di-
agnosed as fatty liver by ultrasound from the outpatient
department of Endocrinology of Zhongshan hospital,
Fudan university between Nov. 2005 and Apr. 2006
were recruited for this study.
Subjects with excessive alcohol consumption (≥30 g/d
in men and ≥20 g/d in women) were excluded from the
study. Subjects were also excluded if they had known
diabetes mellitus, hepatitis B or C or other liver diseases,
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(statins, fibrates) drugs, or other drugs that may impact
glucose and lipid metabolism. Other exclusion factors
were diseases affecting the metabolic state or not suitable
to participate in this study, for example, hyperthyroidism,
hypothyroidism, mental disease, serious disease with dys-
function of heart, liver, kidney, and cancer, etc.
All subjects underwent comprehensive physical ex-
aminations and routine biochemical analyses of blood.
A 75-g oral glucose tolerance test (OGTT) with a test
of 2 time-points (0 and 120 min post glucose loading)
was performed. Among all subjects, 59 had normal
glucose regulation (NGR), 13 had isolated-impaired
fasting glucose (I-IFG), and 15 had isolated-impaired
glucose tolerance (I-IGT), 5 had IFG and IGT, 14 had
new diagnosed diabetes mellitus.
The study was approved by the human research ethics
committee of Zhongshan hospital, Fudan University and
informed consent was obtained from all subjects.Anthropometric and biochemical measurements
Body mass index (BMI) was calculated as body weight in
kilograms divided by the square of height in meters.
Waist circumference was measured at the midpoint be-
tween the inferior costal margin and the superior border
of the iliac crest on the mid axillary line.
Blood samples were drawn after an overnight fast and
immediately centrifuged. Serum glucose was measured by
the glucoseoxidase method. Serum total cholesterol (TC),
triglycerides (TG), high-density lipoprotein cholesterol
(HDL-c), low-density lipoprotein cholesterol (LDL-c),
and liver enzyme levels were determined by enzymatic
methods with a Hitachi 7600 analyzer (Hitachi, Ltd.
Tokyo, Japan).
Serum insulin (mU/L) was measured with an insulin
radioimmunoassay kit (kit from Beijing North Biotechnol-
ogy Research Institute), which had a reactivity of less than
0.2% to human proinsulin. The inter-assay and intra-assay
coefficients of variation were 5.8% and 11.0% for insulin.
Insulin resistance (IR) and β cell function were esti-
mated using the homeostasis model of assessment
(HOMA). HOMA-IR was calculated as fasting glucose
(mmol/L) × fasting insulin (mU/L)/22.5 and HOMA-β
was calculated as 20 × fasting insulin (mU/L)/[fasting
glucose (mmol/L)-3.5)].
Serum RBP4 (μg/ml) was measured in duplicate by a
sandwich ELISA developed in-house, using affinity-
chromatography purified polyclonal and monoclonal
antibodies generated against recombinant human RBP4
protein. The assay system was subsequently cross-
validated by Western blot analysis. The intra-assay coef-
ficient of variation was 1.8–7.6% and inter-assay was
3.7–8.85% [30].Hyperglycemic clamp
A total of 17 NGT subjects (men = 6, women = 11) under-
went hyperglycemic clamp. None of the subjects was tak-
ing any medications known to affect glucose and lipid
metabolism. Subjects fasted 12 h before the experiments,
in the experiments morning, a dorsal hand vein was can-
nulated in a retrograde fashion and kept in a constant-
temperature device at 50-55°C for sampling arterialized
venous blood. An antecubital vein was cannulated for infu-
sion of 20% glucose. After a 30-min baseline period, serum
glucose concentrations were increased to 13 mmol/L
and subsequently maintained at this level for 150 min
using the glucose clamp technique. During the experi-
ments, blood samples for serum insulin determinations
were obtained at -30,-15, 0, 2, 4, 6, 8, 10, 20, 30, 40, 50,
60, 70, 80, 90, 100, 110, 120, 130, 140, and 150 min [31].
Calculations
First-phase insulin secretion (1PH) was considered the sum
of the serum insulin concentration from 2–10 min of the
hyperglycemic clamp. Increment of 1PH was calculated as
1PH subtracting basal insulin level. Second-phase insulin
secretion (2PH) was calculated as the average serum insulin
concentration from 20–150 min of the clamp. Increment
of 2PH was calculated as 2PH subtracting basal insulin
level. The insulin sensitivity index (ISI) was determined as
the average glucose metabolized rate during the last 30 min
of the hyperglycemic clamp divided by the average serum
insulin concentration during the same interval.
Determination of hepatic fat content with calibrated CT
CT scans was performed using a Marconi MX8000 ma-
chine Philips by the same one experienced doctor to
measure hepatic fat content of patients. CT scan was per-
formed at a voltage of 120 kv, electricity of 292 mA, and a
slice of 6.5 mm with scan time of 3 seconds. Four slices
were acquired in each patient at the following levels: dome
of the liver, cephalad and caudal to the hepatic hilum, and
the inferior margin of the right lobe. No contrast medium
was used. The average of the four Hounsfield values ob-
tained for each slice was measured.
Test tubes containing solutions with CT scan density
(CTD) similar to normal liver (“liver-equivalent”) or “fat-
equivalent material” in variable proportions were prepared
to mimick different degrees of hepatic fat content. At the
time of the CT measurement, the test tubes were placed
on the abdomen of the patient, the CT numbers of the
calibrating solutions were measured at the beginning of
the exam, concurrently with those of the liver. A linear re-
gression of the relative fat content of the test tubes solu-
tion was then calculated, and the CT number of the liver
of the patient derived according to the regression line. The
hepatic fat content (HFC) was expressed as a percentage
of the entire liver [32].
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All analyses were performed using Statistical Package
for the Social Sciences version 16.0 (SPSS Inc., Chicago,
Illinois, USA). Normally distributed data were expressed
as mean ± SD. Data that were not normally distributed, as
determined using the Kolmogorox-Smirnov test, were
logarithmically transformed before analysis. The Student’s
unpaired t test was used for comparison between two
groups. Pearson’s correlation was used to analyze the
relation of serum RBP4 and other parameters. Multiple
stepwise regression analysis was used to examine the
association of HOMA-β and serum RBP4 and other
parameters. In all statistical tests, P values less than
0.05 were considered significant.
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